Biotech

搜索文档
Quince Therapeutics to Host Virtual Investor Day on October 2, 2025
Businesswire· 2025-09-12 04:05
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $QNCX #biotech--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today announced that it will host a virtual Investor Day on Thursday, October 2, 2025, from 10:00 a.m. and 12:00 p.m. Eastern Time. Quince's virtual Investor Day will feature presentations from the company's leadership team who will share the latest clinical development and ...
Avidity Biosciences: 'Strong Buy' Based On Accelerated Approval Filing For Del-Zota (RNA)
Seeking Alpha· 2025-09-12 02:36
This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33. ...
Avidity Biosciences: Maintaining 'Strong Buy' Rating Based On Accelerated Approval Filing For Del-Zota
Seeking Alpha· 2025-09-12 02:36
This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33. ...
Revolution Medicines: Shares Soar On Pancreatic Cancer Study Win - I'm Sold (NASDAQ:RVMD)
Seeking Alpha· 2025-09-12 01:30
If you are interested in keeping up to date with stocks making moves within the biotech, pharma, and healthcare industries and understanding the key trends and catalysts driving valuations ahead of the market, why not subscribe to my weekly newsletter via my Investing Group, Haggerston BioHealth ?The group is for both novice and experienced biotech investors. It provides catalysts to look out for and buy and sell ratings. It also provides product sales and forecasts for all the Big Pharmas, forecasting, int ...
Revolution Medicines: Shares Soar On Pancreatic Cancer Study Win - I'm Sold
Seeking Alpha· 2025-09-12 01:30
If you are interested in keeping up to date with stocks making moves within the biotech, pharma, and healthcare industries and understanding the key trends and catalysts driving valuations ahead of the market, why not subscribe to my weekly newsletter via my Investing Group, Haggerston BioHealth ?The group is for both novice and experienced biotech investors. It provides catalysts to look out for and buy and sell ratings. It also provides product sales and forecasts for all the Big Pharmas, forecasting, int ...
Rosen Law Firm Urges Unicycive Therapeutics, Inc. (NASDAQ: UNCY) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
Businesswire· 2025-09-12 01:00
Sep 11, 2025 1:00 PM Eastern Daylight Time Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/. Rosen Law Firm Urges Unicycive Therapeutics, Inc. (NASDAQ: UNCY) Stockholders with Large Losses to Contact the Firm for Information About Their Rights Share NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class acti ...
ImmunityBio: Still Too Early To Judge Anktiva, Although Clock Is Ticking
Seeking Alpha· 2025-09-12 00:26
If you are interested in keeping up to date with stocks making moves within the biotech, pharma and healthcare industries, and understanding the key trends and catalysts driving valuations ahead of the market, why not subscribe to my weekly newsletter via my Investing Group, Haggerston BioHealth ?The group is for both novice and experienced biotech investors. It provides catalysts to look out for and buy and sell ratings. It also provides product sales and forecasts for all the Big Pharmas, forecasting, int ...
Galapagos NV (GLPG)’ CAR-T Therapy Hits 97% Response Rate in Lymphoma Trial
Yahoo Finance· 2025-09-11 23:18
In this article, we will be taking a look at the 11 Best Performing Biotech Stocks So Far in 2025. Galapagos NV is one of them. Galapagos NV (NASDAQ:GLPG) is a Belgian-based firm and is carving out a leading position in next-generation oncology through its CAR-T programs and decentralized manufacturing model, designed to deliver faster, more accessible treatments for patients with hematological cancers. It is among the best performing stocks. Galapagos NV (NASDAQ:GLPG)’s momentum centers on GLPG5101, a ...
Caris Life Sciences, Inc. (CAI) Secures FDA Nod for Revolutionary Tumor Profiling Test
Yahoo Finance· 2025-09-11 23:17
In this article, we will be taking a look at the 11 Best Performing Biotech Stocks So Far in 2025. Caris Life Sciences, Inc. stands tenth among them. Caris Life Sciences, Inc. (NASDAQ:CAI) is a biotech company that is driven by its breakthroughs in precision oncology, expansion of AI-powered molecular diagnostics, and recent FDA approvals. A pivotal development came with the FDA approval of Caris’s MI Cancer Seek platform, the first diagnostic to combine whole exome and whole transcriptome sequencing on ...
PTC Therapeutics, Inc. (PTCT) Launches SUFIANCE for PKU
Yahoo Finance· 2025-09-11 23:15
In this article, we will be taking a look at the 11 Best Performing Biotech Stocks So Far in 2025. PTC Therapeutics, Inc. is one of them. PTC Therapeutics, Inc. (NASDAQ:PTCT) is reinforcing its position in rare disease innovation with the launch of SUFIANCE (sepiapterin) for phenylketonuria (PKU). Recently approved by both the FDA and EU, SUFIANCE rolled out in Germany in July 2025, with a U.S. launch imminent. The drug is projected to generate over $1 billion annually in the U.S., making it a central dri ...